The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.

Li X, Qie S, Wang X, Zheng Y, Liu Y, Liu G

Endocrine12 Aug 2018Cited by 20 (Europe PMC)

PMID30101378DOI10.1007/s12020-018-1708-zPepBankPUB-30101378

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide reduced HbA1c more than placebo or other agents in a meta-analysis of 11 studies.
In plain wordsIn people with type 2 diabetes, semaglutide lowered HbA1c more than placebo or other drugs in pooled trials.
Peptide
Semaglutide
Outcome
DecreaseHbA1c reduction
Study
n = 9,519
Comparator
Placebo or other antihyperglycaemic agents
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD
1.03%
HbA1c reduction
Source sentences
Summary
haemoglobin A1c (HbA1c) [MD 1.03%, 95% CI (0.85%, 1.22%), p < 0.00001]
2 context sentences(design, population, supporting numbers)
Summary · context
Randomised controlled trials (RCTs) comparing semaglutide with placebo or other AHAs in T2DM patients were included in our meta-analysis.
Summary · context
A total of 11 studies with 9519 patients were included in our meta-analysis.
Report a problemFND-3010137801
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide reduced self-measured plasma glucose more than placebo or other agents in a meta-analysis.
In plain wordsIn people with type 2 diabetes, semaglutide lowered home-measured glucose more than placebo or other drugs in pooled trials.
Peptide
Semaglutide
Outcome
DecreaseSelf-measured plasma glucose
Study
n = 9,519
Comparator
Placebo or other antihyperglycaemic agents
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD
1.19 mmol/L
SMPG reduction
Source sentences
Summary
self-measured plasma glucose (SMPG) [MD 1.19 mmol/L, 95% CI (0.84 mmol/L, 1.53 mmol/L), p < 0.00001]
2 context sentences(design, population, supporting numbers)
Summary · context
Randomised controlled trials (RCTs) comparing semaglutide with placebo or other AHAs in T2DM patients were included in our meta-analysis.
Summary · context
A total of 11 studies with 9519 patients were included in our meta-analysis.
Report a problemFND-3010137802
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide reduced fasting plasma glucose more than placebo or other agents in a meta-analysis.
In plain wordsIn people with type 2 diabetes, semaglutide lowered fasting glucose more than placebo or other drugs in pooled trials.
Peptide
Semaglutide
Outcome
DecreaseFasting plasma glucose
Study
n = 9,519
Comparator
Placebo or other antihyperglycaemic agents
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD
1.33 mmol/L
FPG reduction
Source sentences
Summary
fasting plasma glucose (FPG) [MD 1.33 mmol/L, 95% CI (0.97 mmol/L, 1.69 mmol/L), p < 0.00001]
2 context sentences(design, population, supporting numbers)
Summary · context
Randomised controlled trials (RCTs) comparing semaglutide with placebo or other AHAs in T2DM patients were included in our meta-analysis.
Summary · context
A total of 11 studies with 9519 patients were included in our meta-analysis.
Report a problemFND-3010137803
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide reduced weight more than placebo or other agents in a meta-analysis.
In plain wordsIn people with type 2 diabetes, semaglutide reduced weight more than placebo or other drugs in pooled trials.
Peptide
Semaglutide
Outcome
DecreaseWeight reduction
Study
n = 9,519
Comparator
Placebo or other antihyperglycaemic agents
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
MD
3.61 kg
weight reduction
Source sentences
Summary
weight [MD 3.61 kg, 95% CI (3.05 kg, 4.17 kg), p < 0.00001]
2 context sentences(design, population, supporting numbers)
Summary · context
Randomised controlled trials (RCTs) comparing semaglutide with placebo or other AHAs in T2DM patients were included in our meta-analysis.
Summary · context
A total of 11 studies with 9519 patients were included in our meta-analysis.
Report a problemFND-3010137804
05HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, semaglutide increased the proportion reaching HbA1c below 7.0% versus placebo or other agents (RR 2.26).
In plain wordsIn people with type 2 diabetes, more people reached an HbA1c below 7.0% with semaglutide than with placebo or other drugs.
Peptide
Semaglutide
Outcome
IncreaseParticipants achieving HbA1c below 7.0%
Study
n = 9,519
Comparator
Placebo or other antihyperglycaemic agents
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
RR
2.26 ratio
HbA1c < 7.0%
Source sentences
Summary
significantly increased participants who achieved HbA1c < 7.0% [RR 2.26, 95% CI (1.89, 2.70), p < 0.00001] in T2DM patients.
2 context sentences(design, population, supporting numbers)
Summary · context
Randomised controlled trials (RCTs) comparing semaglutide with placebo or other AHAs in T2DM patients were included in our meta-analysis.
Summary · context
A total of 11 studies with 9519 patients were included in our meta-analysis.
Report a problemFND-3010137805
06HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, semaglutide increased the incidence of adverse events versus controls (RR 1.06) in a meta-analysis.
In plain wordsIn people with type 2 diabetes, side effects were slightly more common with semaglutide than with controls in pooled trials.
Peptide
Semaglutide
Outcome
IncreaseAdverse events
Study
n = 9,519
Comparator
Placebo or other antihyperglycaemic agents
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
RR
1.06 ratio
adverse events
Source sentences
Summary
Semaglutide had a significant increase in the incidence of adverse events (AEs) [RR 1.06, 95% CI (1.02, 1.11), p < 0.0001]
2 context sentences(design, population, supporting numbers)
Summary · context
Randomised controlled trials (RCTs) comparing semaglutide with placebo or other AHAs in T2DM patients were included in our meta-analysis.
Summary · context
A total of 11 studies with 9519 patients were included in our meta-analysis.
Report a problemFND-3010137806
07HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, semaglutide showed a similar incidence of serious adverse events versus controls (RR 0.94) in a meta-analysis.
In plain wordsIn people with type 2 diabetes, serious side effects were about as common with semaglutide as with controls in pooled trials.
Peptide
Semaglutide
Outcome
No significant changeSerious adverse events
Study
n = 9,519
Comparator
Placebo or other antihyperglycaemic agents
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
RR
0.94 ratio
serious adverse events
Source sentences
Summary
an analogous incidence in serious adverse events (SAEs) [RR 0.94, 95% CI (0.86, 1.02), p = 0.11]
2 context sentences(design, population, supporting numbers)
Summary · context
Randomised controlled trials (RCTs) comparing semaglutide with placebo or other AHAs in T2DM patients were included in our meta-analysis.
Summary · context
A total of 11 studies with 9519 patients were included in our meta-analysis.
Report a problemFND-3010137807
08HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, semaglutide showed a similar incidence of severe or confirmed symptomatic hypoglycaemia versus controls (RR 0.93) in a meta-analysis.
In plain wordsIn people with type 2 diabetes, low blood sugar events were about as common with semaglutide as with controls in pooled trials.
Peptide
Semaglutide
Outcome
No significant changeHypoglycaemic events
Study
n = 9,519
Comparator
Placebo or other antihyperglycaemic agents
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated
Measurements
RR
0.93 ratio
hypoglycaemic events
Source sentences
Summary
hypoglycaemic events (severe or blood glucose (BG)-confirmed symptomatic) [RR 0.93, 95% CI (0.74, 1.16), p = 0.50]
2 context sentences(design, population, supporting numbers)
Summary · context
Randomised controlled trials (RCTs) comparing semaglutide with placebo or other AHAs in T2DM patients were included in our meta-analysis.
Summary · context
A total of 11 studies with 9519 patients were included in our meta-analysis.
Report a problemFND-3010137808

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.